Novan, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. The company's clinical stage product candidates comprise SB208, a topical antifungal gel that is in Phase II proof-of-concept trial for the treatment of athlete's foot and fungal nail infections; and SB414, a topical cream, which is in Phase Ib trial for the treatment of inflammatory skin diseases, such as psoriasis and atopic dermatitis. It has a license agreement with Sato Pharmaceutical Co., Ltd. Novan, Inc. was founded in 2006 and is headquartered in Morrisville, North Carolina.
Industry, Sector and Symbol
Stock Exchange VTX
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolVTX:NOVN
CUSIPN/A
Phone+41-61-3241111
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins15.47%
Return on Equity11.16%
Return on Assets6.10%
Miscellaneous
EmployeesN/A
Outstanding Shares2,330,000,000
Market Cap$206.54 billion
Novartis (VTX:NOVN) Frequently Asked Questions
What is Novartis' stock symbol?
Novartis trades on the VTX under the ticker symbol "NOVN."
What price target have analysts set for NOVN?
20 Wall Street analysts have issued 1-year target prices for Novartis' stock. Their forecasts range from CHF 79 to CHF 100. On average, they anticipate Novartis' stock price to reach CHF 88.85 in the next year. This suggests a possible upside of 13.4% from the stock's current price. View Analyst Price Targets for Novartis.
What is the consensus analysts' recommendation for Novartis?
20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 11 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis.
Who are some of Novartis' key competitors?
Some companies that are related to Novartis include CSL (CSL), Shire (SHP), UCB S A/ADR (UCBJY), Novozymes A/S (NVZMF), GENMAB A/S/S (GMXAY), ABLYNX NV/ADR (ABLX), MorphoSys (MPSYY), BTG (BTG), Abcam (ABC), MorphoSys (MOR), Almirall (LBTSF), Sosei Group (SOLTF), Sirtex Medical (SRX), Genus (GNS) and Biotest (BIO).
Who are Novartis' key executives?
Novartis' management team includes the folowing people:
- Mr. G. Kelly Martin, CEO & Director (Age 59)
- Dr. Nathan Stasko, Co-Founder, Pres, Chief Scientific Officer & Director (Age 38)
- Mr. Jeff N. Hunter, Exec. VP, Chief Bus. Officer & Company Sec. (Age 61)
- Ms. Paula Brown Stafford, Chief Devel. Officer & Director (Age 53)
- Mr. Andrew Novak, VP & Chief Accounting Officer
What is Novartis' stock price today?
One share of NOVN stock can currently be purchased for approximately CHF 78.38.
How big of a company is Novartis?
Novartis has a market capitalization of $206.54 billion.
What is Novartis' official website?
How can I contact Novartis?
Novartis' mailing address is Lichtstrasse 35, BASEL, 4056, Switzerland. The company can be reached via phone at +41-61-3241111.
MarketBeat Community Rating for Novartis (VTX NOVN)
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NOVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NOVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
